Diabetic Foot Ulcers Pipeline Insight

DelveInsight’s, “Diabetic Foot Ulcers - Pipeline Insight, 2021,” report provides comprehensive insights about 34+ companies and 34+ pipeline drugs in Diabetic Foot Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Diabetic Foot Ulcers Understanding

Diabetic Foot Ulcers: Overview

A Diabetic Foot Ulcers is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of Diabetic Foot Ulcersss requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.


"Diabetic Foot Ulcers - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Foot Ulcers pipeline landscape is provided which includes the disease overview and Diabetic Foot Ulcers treatment guidelines. The assessment part of the report embraces, in depth Diabetic Foot Ulcers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Foot Ulcers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Foot Ulcers R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Foot Ulcers.

Diabetic Foot Ulcers Emerging Drugs Chapters

This segment of the Diabetic Foot Ulcers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Diabetic Foot Ulcers Emerging Drugs


Galnobax: NovaLead Pharma

Galnobax is a topical gel for non-healing chronic wounds. It is a repurposed generic drug molecule, which is in Phase III clinical studies for the treatment of Diabetic Foot Ulcers (DFU).


Nemonoxacin: TaiGen Biotechnology

Nemonoxacin is a non-fluorinated quinolone (NFQ) based bacterial topoisomerase inhibitor. The drug is in Phase II clinical developmental studies for the treatment of Diabetic Foot Ulcers. The drug is approved for the treatment of community-acquired pneumonia.

Further product details are provided in the report……..

Diabetic Foot Ulcers: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Foot Ulcers drugs segregated based on following parameters that define the scope of the report, such as:

  • • Major Players in Diabetic Foot Ulcers

There are approx. 34+ key companies which are developing the therapies for Diabetic Foot Ulcers. The companies which have their Diabetic Foot Ulcers drug candidates in the most advanced stage, i.e. Phase II include, NovaLead Pharma.

Phases

DelveInsight’s report covers around 34+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Diabetic Foot Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Foot Ulcers: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic Foot Ulcers therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Foot Ulcers drugs.

Diabetic Foot Ulcers Report Insights

  • Diabetic Foot Ulcers Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Diabetic Foot Ulcers Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Diabetic Foot Ulcers drugs?
  • How many Diabetic Foot Ulcers drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Foot Ulcers?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Foot Ulcers therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic Foot Ulcers and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Diabetic Foot Ulcers: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Diabetic Foot Ulcers – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Diabetic Foot Ulcers companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Diabetic Foot Ulcers Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Galnobax: NovaLead Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Nemonoxacin: TaiGen Biotechnology

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

CHF-6467: Chiesi Farmaceutici

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

  • Comparative Analysis

AP Skin 01: APstem Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Diabetic Foot Ulcers Key Companies

Diabetic Foot Ulcers Key Products

Diabetic Foot Ulcers- Unmet Needs

Diabetic Foot Ulcers- Market Drivers and Barriers

Diabetic Foot Ulcers- Future Perspectives and Conclusion

Diabetic Foot Ulcers Analyst Views

Diabetic Foot Ulcers Key Companies

Appendix

List of Table

Table 1: Total Products for Diabetic Foot Ulcers

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Diabetic Foot Ulcers

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• NovaLead Pharma

• Helixmith

• ShangHai HaiHe Pharmaceutical

• Beyond Air

• TaiGen Biotechnology

• RHEACELL

• Technophage

• Transwell Biotech

• Roche

• Chiesi Farmaceutici

• Blue Blood Biotech

• Cynata Therapeutics

• ZZ Biotech

• APstem Therapeutics

• Lewis and Clark Pharmaceuticals

• Destiny Pharma

• SCM Lifescience

  • Tags:
  • Diabetic Foot Ulcers Pipeline
  • Diabetic Foot Ulcers clinical tria...
  • Diabetic Foot Ulcers companies
  • Diabetic Foot Ulcers drugs
  • Diabetic Foot Ulcers therapies
  • Diabetic Foot Ulcers treatment alg...
  • Diabetic Foot Ulcers pipeline drug...
  • Diabetic Foot Ulcers pipeline comp...

Forward to Friend

Need A Quote